Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2019 Apr 11;14(4):e0215491. doi: 10.1371/journal.pone.0215491

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi
PMCID: PMC6459474  PMID: 30973957

Notice of Republication

An incorrect version of S2 File was published in error. This article was republished on April 2, 2019 to correct for this error. Please download this article again to view the correct version.

Reference

  • 1.Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, et al. (2019) Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE 14(2): e0212989 10.1371/journal.pone.0212989 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES